Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Aug 2022. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
5097894011 | Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
5097895012 | Levocetirizine dihydrochloride 2.5 mg and montelukast (as montelukast sodium) 4 mg tablet for oral suspension | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
5259832012 | Levocetirizine dihydrochloride 2.5 mg and montelukast (as montelukast sodium) 4 mg dispersible oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Is a | Product containing only levocetirizine and montelukast in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has manufactured dose form | Tablet for conventional release oral suspension (dose form) | true | Inferred relationship | Some | ||
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has precise active ingredient | Montelukast sodium | true | Inferred relationship | Some | 1 | |
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has basis of strength substance (attribute) | Montelukast (substance) | true | Inferred relationship | Some | 1 | |
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has precise active ingredient | Levocetirizine dihydrochloride (substance) | true | Inferred relationship | Some | 2 | |
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has basis of strength substance (attribute) | Levocetirizine dihydrochloride (substance) | true | Inferred relationship | Some | 2 | |
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets